Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib + Palbociclib in Advanced Dedifferentiated Liposarcoma
NCT06843967Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in dedifferentiated liposarcoma (DDL), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2025; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06843967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843967.